Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma

This study is a prospective, single center, open label, single arm clinical study. Select resectable locally advanced (cT3-4aN0M0, cT1-3N1-2M0, cII/III stage) esophageal cancer with pathological diagnosis of squamous cell carcinoma for inclusion, receive pembrolizumab combined with platinum containing dual drug (albumin paclitaxel+carboplatin) treatment for 2 courses, and undergo surgery. After surgery, continue pembrolizumab immunotherapy. Using pCR as the main endpoint of the study

Trial Details

NCT ID
NCT06304350
Phase
PHASE2
Sponsor
Tongji University
Status
RECRUITING
Cancer Type
Squamous Cell Esophageal Cancer
Interventions
  • Combination of pembrolizumab and platinum containing dual drugs
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Baseline stage resectable cII/III esophageal squamous cell carcinoma (8th UICC TNM stage);
  • Failure to receive anti-tumor treatment for esophageal squamous cell carcinoma;
  • Age range from 18 to 75 years old;
  • There are no surgical contraindications in the preoperative evaluation of various organ functions;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Esophageal Cancer Trials on Trialify →